Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-19T18:42:18.082Z Has data issue: false hasContentIssue false
  • English
  • Français

Quantification of Carbamazepine in Tablets by Powder X-ray Diffractometry

Published online by Cambridge University Press:  06 March 2019

R. Suryanarayanan
R. Suryanarayanan*
Affiliation:
Department of Pharmaceutics, College of Pharmacy, University of Minnesota 308 Harvard Street S. E., Minneapolis, MN 55455, U. S. A.
Get access

Abstract

A powder x-ray diffraction technique has been developed for the quantification of carbamazepine in tablets. The other tablet ingredients were microcrystalline cellulose, starch, stearic acid and silicon dioxide. The tablets were ground in a ball mill and the powder mixed with lithium fluoride (20% w/w) which was the internal standard. Five lines of carbamazepine with d-spacings of 3.38, 3.34, 3.28, 3.26 and 3.23 Å and the 2.01 Å line of lithium fluoride were used for the quantitative analysis. A plot of the intensity ratio (sum of the intensities of the lines of carbamazepine/intensity of die lithium fluoride line) as a function of the weight fraction of carbamazepine in the tablets resulted in a straight line. Using this standard curve, the carbamazepine content in “unknown” tablets was determined and ranged between 98.6 and 101.6% of the actual drug content. The coefficient of variation in the determinations ranged between 0.28 and 2.1%.

Type
VIII. Qualitative and Quantiative Phase Analysis by XRD
Information
Advances in X-Ray Analysis , Volume 34: Thirty-Ninth Annual Conference on Applications of X-ray Analysis, July 30 - August 3, 1990 , 1990 , pp. 417 - 427
Copyright
Copyright © International Centre for Diffraction Data 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alexander, L. and Klug, H. P., Anal. Chem. 20: 886–889 (1948).Google Scholar
Brindley, G. W., in Brown, G. (ed.), The X-ray Identification and Crystal Structures of Clay Minerals, 2nd ed., Mineralogical Society, London, 1961, p. 492.Google Scholar
Himes, V. L., Mighell, A. D. and De Camp, W. H., Acta Cryst. B37: 2242–2245 (1981).Google Scholar
King, R. E. and Schwartz, J. B. in Gennaro, A. R. (ed.), Remington's Pharmaceutical Sciences, 17th. edition, Mack Publishing Co., Easton, PA., 1985, pp. 1621–1623.Google Scholar
Klug, H. P. and Alexander, L. E., X-ray Diffraction Procedures for Polycrystalline and Amorphous Materials, 2nd ed., Wiley, New York, NY, 1974, pp. 360–364, 368, 369, 536-538, 540 and 541.Google Scholar
Lefebvre, C., Guyot-Hermann, A. M. Draguet-Brughmans, M., Bouche, R., and Guyot, J. C., Drug Development and Industrial Pharmacy, 12: 1913–1927 (1986).Google Scholar
The Merck Index, Windholz, M. (ed.), 10th edition, Merck and Co., Rahway, NJ, 1983, p. 793.Google Scholar
Morris, M. C. McMurdie, H. R. Evans, E. H., Paretzkin, B., de Groot, J. H., Hubbard, C. R. and Carmel, S. J., National Bureau of Standards, Washington, D. C., Monograph 25, Section 16, pp. 1-5, 1975.Google Scholar
Powder Diffraction File, PDF 33-1565 (βVcarbamazepine), International Centre for Diffraction Data, Swarthmore, PA, 1989.Google Scholar
Product information on microcrystalline cellulose provided by FMC Corporation, Philadelphia, PA, 1989. Product information on starch provided by A. E. Staley Manufacturing Company, Decatur, IL, 1989.Google Scholar
Shell, J. W., J. Pharm. Sci., 52: 24–29 (1963).Google Scholar
Suryanarayanan, R., Pharm. Res., 6: 1017–1024 (1989).Google Scholar
Suryanarayanan, R., Powder., 5: 155–159 (1990).Google Scholar
The United States Pharmacopeia, XXII revision, The United States Pharmacopeial Convention, Rockville, MD, 1989.Google Scholar